A new preclinical ultrasound platform for widefield 3D imaging of rodents.
暂无分享,去创建一个
Paul A Dayton | Virginie Papadopoulou | Max Harlacher | Graeme O'Connell | Ryan C Gessner | Stephen R Aylward | Tomasz J. Czernuszewicz | Dženan Zukić | Tomasz J Czernuszewicz | Jonathan Perdomo | Dženan Zukić | S. Aylward | P. Dayton | R. Gessner | J. Rojas | Rajalekha M Rajamahendiran | Max Harlacher | V. Papadopoulou | Juan D Rojas | James Butler | Graeme O'Connell | J. Perdomo | James Butler
[1] S. Lyons,et al. Imaging Mouse Models of Cancer. , 2015, Cancer journal.
[2] Mallika Singh,et al. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. , 2012, Cancer research.
[3] Dimitre Hristov,et al. VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer. , 2016, Cancer research.
[4] D O Cosgrove,et al. Quantitative contrast-enhanced ultrasound imaging: a review of sources of variability , 2011, Interface Focus.
[5] Paul A. Dayton,et al. Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy , 2018, Theranostics.
[6] Paul A. Dayton,et al. Early Assessment of Tumor Response to Radiation Therapy using High-Resolution Quantitative Microvascular Ultrasound Imaging , 2018, Theranostics.
[7] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[8] Dimitre Hristov,et al. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging , 2017, Angiogenesis.
[9] Wolfgang A Weber,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Stuart Foster,et al. Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.
[11] Paul A Dayton,et al. Mapping microvasculature with acoustic angiography yields quantifiable differences between healthy and tumor-bearing tissue volumes in a rodent model. , 2012, Radiology.
[12] Dimitre Hristov,et al. Three-Dimensional Ultrasound Molecular Imaging of Angiogenesis in Colon Cancer Using a Clinical Matrix Array Ultrasound Transducer , 2015, Investigative radiology.
[13] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Nathalie Lassau,et al. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. , 2013, European journal of radiology.
[15] Jonathan R Lindner,et al. Quantitative assessment of placental perfusion by contrast-enhanced ultrasound in macaques and human subjects. , 2016, American journal of obstetrics and gynecology.
[16] Paul A Dayton,et al. Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion. , 2011, Ultrasound in medicine & biology.
[17] Sanjiv S Gambhir,et al. Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Andras Lasso,et al. PLUS: Open-Source Toolkit for Ultrasound-Guided Intervention Systems , 2014, IEEE Transactions on Biomedical Engineering.
[19] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[20] François Tranquart,et al. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. , 2015, Radiology.
[21] François Tranquart,et al. First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study , 2017, Investigative radiology.
[22] W. Pao,et al. How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Paul A Dayton,et al. A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound , 2017, Ultrasonic imaging.
[24] J. Yeh,et al. A Comparative Evaluation of Ultrasound Molecular Imaging, Perfusion Imaging, and Volume Measurements in Evaluating Response to Therapy in Patient-Derived Xenografts , 2013, Technology in cancer research & treatment.
[25] B. Ariff,et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[26] Molly L Flexman,et al. Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. , 2012, Ultrasound in medicine & biology.
[27] F. Stuart Foster,et al. Acoustic Angiography: A New Imaging Modality for Assessing Microvasculature Architecture , 2013, Int. J. Biomed. Imaging.
[28] L. Bolondi,et al. Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma , 2015, Molecular Imaging and Biology.
[29] P. Dayton,et al. Vascular channels formed by subpopulations of PECAM1+ melanoma cells , 2014, Nature Communications.
[30] Paul A Dayton,et al. Improving Sensitivity in Ultrasound Molecular Imaging by Tailoring Contrast Agent Size Distribution: In Vivo Studies , 2010, Molecular imaging.
[31] Ingrid Leguerney,et al. Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin. , 2015, Ultrasound in medicine & biology.
[32] Fabian Kiessling,et al. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects. , 2016, Radiology.
[33] Jimmy Espinoza,et al. Applications of 2‐Dimensional Matrix Array for 3‐ and 4‐Dimensional Examination of the Fetus , 2006, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[34] Vicky Goh,et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies , 2010, Cancer biology & therapy.
[35] Fabian Kiessling,et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38) , 2011, European Radiology.
[36] Fabio Cominelli,et al. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. , 2006, Gastroenterology.
[37] Linda Chami,et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.
[38] Michael B Lawrence,et al. Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[39] Maximilian Reiser,et al. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation , 2017, PloS one.
[40] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[41] K. Cox,et al. Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation , 2015, Annals of Surgical Oncology.
[42] Paul A Dayton,et al. Quantification of Microvascular Tortuosity during Tumor Evolution Using Acoustic Angiography. , 2015, Ultrasound in medicine & biology.
[43] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[44] Alexandra Branzan Albu,et al. A Morphology-Based Approach for Interslice Interpolation of Anatomical Slices From Volumetric Images , 2008, IEEE Transactions on Biomedical Engineering.
[45] Paul A Dayton,et al. Quantitative Volumetric Perfusion Mapping of the Microvasculature Using Contrast Ultrasound , 2010, Investigative radiology.
[46] Dimitre Hristov,et al. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. , 2017, Radiology.
[47] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.